Mucosal barrier dysfunction to luminal microbes plays a crucial role in the development of intestinal inflammation in Crohn’s disease (CD). Recently, an inflammatory form of intestinal epithelial cell (IEC) death resulting from innate immune activation, termed pyroptosis, was proposed as a possible cause of this barrier defect. We hypothesize that ileal IEC pyroptosis, as a marker of mucosal barrier dysfunction, may be used to predict clinical response of biologic therapy in CD patients. Vedolizumab is an anti-integrin monoclonal antibody approved for the treatment of CD.